396 related articles for article (PubMed ID: 15994752)
1. High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone.
Mueller A; Dittrich R; Binder H; Kuehnel W; Maltaris T; Hoffmann I; Beckmann MW
Eur J Endocrinol; 2005 Jul; 153(1):107-13. PubMed ID: 15994752
[TBL] [Abstract][Full Text] [Related]
2. Effects on the male endocrine system of long-term treatment with gonadotropin-releasing hormone agonists and estrogens in male-to-female transsexuals.
Mueller A; Binder H; Cupisti S; Hoffmann I; Beckmann MW; Dittrich R
Horm Metab Res; 2006 Mar; 38(3):183-7. PubMed ID: 16673210
[TBL] [Abstract][Full Text] [Related]
3. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
Diamond T; Campbell J; Bryant C; Lynch W
Cancer; 1998 Oct; 83(8):1561-6. PubMed ID: 9781950
[TBL] [Abstract][Full Text] [Related]
4. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist.
Dittrich R; Binder H; Cupisti S; Hoffmann I; Beckmann MW; Mueller A
Exp Clin Endocrinol Diabetes; 2005 Dec; 113(10):586-92. PubMed ID: 16320157
[TBL] [Abstract][Full Text] [Related]
5. Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study.
Ruetsche AG; Kneubuehl R; Birkhaeuser MH; Lippuner K
Osteoporos Int; 2005 Jul; 16(7):791-8. PubMed ID: 15502960
[TBL] [Abstract][Full Text] [Related]
6. Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption.
Anderson FH; Francis RM; Peaston RT; Wastell HJ
J Bone Miner Res; 1997 Mar; 12(3):472-8. PubMed ID: 9076591
[TBL] [Abstract][Full Text] [Related]
7. Testosterone increases bone mineral density in female-to-male transsexuals: a case series of 15 subjects.
Turner A; Chen TC; Barber TW; Malabanan AO; Holick MF; Tangpricha V
Clin Endocrinol (Oxf); 2004 Nov; 61(5):560-6. PubMed ID: 15521957
[TBL] [Abstract][Full Text] [Related]
8. High bone density in hyperandrogenic women: effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement.
Simberg N; Tiitinen A; Silfvast A; Viinikka L; Ylikorkala O
J Clin Endocrinol Metab; 1996 Feb; 81(2):646-51. PubMed ID: 8636283
[TBL] [Abstract][Full Text] [Related]
9. Low body size and elevated sex-hormone binding globulin distinguish men with idiopathic vertebral fracture.
Evans SF; Davie MW
Calcif Tissue Int; 2002 Jan; 70(1):9-15. PubMed ID: 11907702
[TBL] [Abstract][Full Text] [Related]
10. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.
Di Somma C; Colao A; Di Sarno A; Klain M; Landi ML; Facciolli G; Pivonello R; Panza N; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1998 Mar; 83(3):807-13. PubMed ID: 9506732
[TBL] [Abstract][Full Text] [Related]
11. Obesity as a protective factor for postmenopausal osteoporosis.
Albala C; Yáñez M; Devoto E; Sostin C; Zeballos L; Santos JL
Int J Obes Relat Metab Disord; 1996 Nov; 20(11):1027-32. PubMed ID: 8923160
[TBL] [Abstract][Full Text] [Related]
12. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
Smith MR; McGovern FJ; Zietman AL; Fallon MA; Hayden DL; Schoenfeld DA; Kantoff PW; Finkelstein JS
N Engl J Med; 2001 Sep; 345(13):948-55. PubMed ID: 11575286
[TBL] [Abstract][Full Text] [Related]
13. Sex hormone-binding globulin, estradiol, and bone turnover markers in male osteoporosis.
Lormeau C; Soudan B; d'Herbomez M; Pigny P; Duquesnoy B; Cortet B
Bone; 2004 Jun; 34(6):933-9. PubMed ID: 15193539
[TBL] [Abstract][Full Text] [Related]
14. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
Lange U; Teichmann J; Müller-Ladner U; Strunk J
Rheumatology (Oxford); 2005 Dec; 44(12):1546-8. PubMed ID: 16263785
[TBL] [Abstract][Full Text] [Related]
15. [Maximal androgen blockade little influences bone mineral density in prostate cancer patients].
Sun GF; Yang B; Zhu H; Li NC; Na YQ
Zhonghua Nan Ke Xue; 2012 Nov; 18(11):978-81. PubMed ID: 23214245
[TBL] [Abstract][Full Text] [Related]
16. The association of endogenous hormone concentrations and bone mineral density measures in pre- and perimenopausal women of four ethnic groups: SWAN.
Sowers MR; Finkelstein JS; Ettinger B; Bondarenko I; Neer RM; Cauley JA; Sherman S; Greendale GA;
Osteoporos Int; 2003 Jan; 14(1):44-52. PubMed ID: 12577184
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones.
van Kesteren P; Lips P; Gooren LJ; Asscheman H; Megens J
Clin Endocrinol (Oxf); 1998 Mar; 48(3):347-54. PubMed ID: 9578826
[TBL] [Abstract][Full Text] [Related]
18. Age, body mass index, current smoking history, and serum insulin-like growth factor-I levels associated with bone mineral density in middle-aged Korean men.
Rhee EJ; Oh KW; Lee WY; Kim SW; Oh ES; Baek KH; Kang MI; Park CY; Choi MG; Yoo HJ; Park SW
J Bone Miner Metab; 2004; 22(4):392-8. PubMed ID: 15221500
[TBL] [Abstract][Full Text] [Related]
19. Hormonal and anthropometric predictors of bone mass in healthy elderly men: major effect of sex hormone binding globulin, parathyroid hormone and body weight.
Martínez Díaz-Guerra G; Hawkins F; Rapado A; Ruiz Díaz MA; Díaz-Curiel M
Osteoporos Int; 2001; 12(3):178-84. PubMed ID: 11315235
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men.
Gennari L; Merlotti D; Martini G; Gonnelli S; Franci B; Campagna S; Lucani B; Dal Canto N; Valenti R; Gennari C; Nuti R
J Clin Endocrinol Metab; 2003 Nov; 88(11):5327-33. PubMed ID: 14602769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
